Cost analysis of bivalirudin in percutaneous coronary intervention.
Lauer
M A
MA
Department of Cardiovascular Research, Borgess Hospital Research Institute, 1521 Gull Road, Kalamazoo, MI 49001, USA. mlauer@borgess.com.
D000787:Angina Pectoris / Q000191:economics / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use; D000991:Antithrombins / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D006470:Hemorrhage / Q000191:economics / Q000517:prevention & control; D006493:Heparin / Q000191:economics / Q000627:therapeutic use; D024764:Hirudin Therapy; D006629:Hirudins / Q000031:analogs & derivatives* / Q000191:economics*; D006801:Humans; D010446:Peptide Fragments / Q000191:economics* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000191:economics* / Q000627:therapeutic use; D012008:Recurrence; D015912:Thrombolytic Therapy / Q000191:economics*
D000925:Anticoagulants; D000991:Antithrombins; D006629:Hirudins; D010446:Peptide Fragments; D011994:Recombinant Proteins; D006493:Heparin; C074619:bivalirudin